Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases - Wikidata - wikimedia - TriplyDB

Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases

Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases

http://www.wikidata.org/entity/Q34731307

about

Constitutively active NF-kappaB triggers systemic TNFalpha-dependent inflammation and localized TNFalpha-independent inflammatory disease.Heart failure and the brain: new perspectives.Identification of autoimmune gene signatures in autism.The changing face of spondyloarthropathies under TNF α blockade.Population pharmacokinetics of rhTNFR-Fc in healthy Chinese volunteers and in Chinese patients with Ankylosing spondylitis.Metabolic syndrome and chronic arthritis: effects of anti-TNF-α therapy.Comparison of the Intravenous and Epidural Administration of Tumor Necrosis Factor-alpha Antagonists in an Experimental Rat Pain Model.Design of a stable cell line producing a recombinant monoclonal anti-TNFα antibody based on a CHO cell line.Treatment of severe recalcitrant plaque psoriasis with single-dose intravenous tumour necrosis factor-alpha antibody (infliximab).

P2860

Q33659872-6BD06B25-1734-458E-8265-224BEC9C2C29 Q35046024-CD8166A8-4457-4651-B949-1D6608741CDB Q35844150-0290B477-BD94-4102-A1A8-BBA93F756198 Q37352654-B2ABDC4A-9EA8-4CDF-B9D6-FEA2DF9AC3A7 Q37729867-D2DA1D56-738B-42D6-9B58-54B9F7C96F9D Q38271745-76C2E93F-1E78-483E-B37B-74B41BB39C32 Q47135664-D05E45D3-1925-4A5C-92EA-B685A8AA1FE0 Q47269867-B1728EEA-CB28-4B59-A3D5-DB10040F1CDC Q53387654-CE6995A9-5F4C-4D88-8392-446C13D7443B

P2860

Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases

http://www.wikidata.org/entity/Q34731307

description

2002 nî lūn-bûn

@nan

2002 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases

@ast

Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases

@en

Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases

@nl

type

label

Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases

@ast

Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases

@en

Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases

@nl

prefLabel

Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases

@ast

Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases

@en

Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases

@nl

P1433

Q34731307-C5EC043D-AB7E-499F-8395-E7CCF645BDC6

P1476

Q34731307-2DC7C735-50A9-4EAD-841F-B5241886E251

P2093

Q34731307-A2B7EE23-B39B-4580-9262-04F8D0A7E41E

P2860

Q34731307-14C19CB5-28E7-429C-AF0A-AA02BCE440BD

Q34731307-17BD1A59-B46B-46BA-BB2B-7EA868156002

Q34731307-23863D3C-C870-42B9-BEBD-06A5CBD13D34

Q34731307-271F2821-660B-4065-97F2-A9930E39516D

Q34731307-28F6175E-2E28-40CE-8A5D-040E4F15453B

Q34731307-2CD51721-A592-42DF-B51E-03AD9677187E

Q34731307-3AE0F9BE-710C-45C1-B8BF-733A49B3FFC1

Q34731307-3BAF72CA-19FA-409F-9386-DCBD559FC367

Q34731307-4A8594D2-765A-4EDD-9433-8F9B9988CBA2

Q34731307-6D1E6CDC-831E-4EF2-B21D-4EE08D369FB7

P2888

Q34731307-BB2ADE5B-7290-4FD3-8737-12DDE8C586DD

P304

Q34731307-48DD041B-B996-4727-A0EC-EB3B8D13DE14

P31

Q34731307-A5B0120A-9908-458F-A883-F0E651A76758

Q34731307-B8C7D100-CFA0-4A2B-AD1B-E302032EEC60

P356

Q34731307-8CDED7B2-9477-48FE-97D9-04AE83E3110E

P478

Q34731307-2231CB74-9460-46B9-90F5-6E02F165B61B

P577

Q34731307-42562ED2-53AB-4126-9AEB-E39D924616F8

P5875

Q34731307-3BF12FEC-E90E-44A7-BDF4-E56748E482DA

P6179

Q34731307-E66E99AA-A5BC-4181-9876-7881D75DC6EA

P698

Q34731307-F76DF187-548B-441F-90FD-10A615E7E89C

P921

Q34731307-3FF4456D-66BC-49DA-B621-1FE8CCCEA6E9

Q34731307-432B2899-0866-460F-B8B6-18A106195A5E

Q34731307-5A586720-2D35-4350-8765-8BE382F443AC

Q34731307-5D364E4C-49AA-4A3C-8E74-8B08ABE6EC37

Q34731307-623B0DFF-896E-4A12-B12B-C198710071A1

Q34731307-66ED5994-F0E9-4B49-A147-86A8EAF19ED6

Q34731307-76EE22AB-F568-4BDF-A848-BD9231A2FA8B

P932

Q34731307-A072F1A4-972B-4B4D-8487-1923A85C17E5

P356

P1433

Arthritis Research and Therapy

P1476

Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases

@en

P2093

Joachim R Kalden

http://www.w3.org/2001/XMLSchema#string

P2860

Still's disease in the adult

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Role of cytokines in rheumatoid arthritis

Therapeutic advances in ankylosing spondylitis.

Infliximab for the treatment of fistulas in patients with Crohn's disease.

Thalidomide: current and potential clinical applications.

P2888

P304

S34-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/AR552

http://www.w3.org/2001/XMLSchema#string

P478

4 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2002-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11268681

http://www.w3.org/2001/XMLSchema#string

P6179

1017419008

http://www.w3.org/2001/XMLSchema#string

P698

12110156

http://www.w3.org/2001/XMLSchema#string

P921

Tumor necrosis factor

cell surface receptor

monoclonal antibody

membrane proteins

P932

3238220

http://www.w3.org/2001/XMLSchema#string